Explore the vast range of titles available.

Using expression profiles from postmortem prefrontal cortex samples of 624 dementia patients and non‐demented controls, we investigated global disruptions in the co‐regulation of genes in two neurodegenerative diseases, late‐onset Alzheimer's disease (AD) and Huntington's disease (HD). We identified networks of differentially co‐expressed (DC) gene pairs that either gained or lost correlation in disease cases relative to the control group, with the former dominant for both AD and HD and both patterns replicating in independent human cohorts of AD and aging. When aligning networks of DC patterns and physical interactions, we identified a 242‐gene subnetwork enriched for independent AD/HD signatures. This subnetwork revealed a surprising dichotomy of gained/lost correlations among two inter‐connected processes, chromatin organization and neural differentiation, and included DNA methyltransferases, DNMT1 and DNMT3A , of which we predicted the former but not latter as a key regulator. To validate the inter‐connection of these two processes and our key regulator prediction, we generated two brain‐specific knockout (KO) mice and show that Dnmt1 KO signature significantly overlaps with the subnetwork ( P = 3.1 × 10 −12 ), while Dnmt3a KO signature does not ( P  = 0.017). Synopsis Network analysis of changes in gene co‐regulation, between large sets of Alzheimer's (AD) or Huntington's (HD) disease versus control brains, reveals that opposing dysregulation of two interacting processes, chromatin organization and neural differentiation, underlies both AD and HD. Postmortem prefrontal cortex samples of over 600 dementia patients (late‐onset AD or HD) and non‐demented controls were expression profiled. Pronounced global changes were observed in the gene–gene co‐expression patterns in AD or HD patients relative to the control group and revealed novel neurodegeneration‐associated genes. Network alignment uncovered shared dysregulation of two inter‐connected processes, chromatin organization and neural differentiation, as a common pathology of AD and HD. DNA methyltransferase, DNMT1 , was validated as a key regulator of the inter‐connection between these two processes, using RNAseq data from brain‐specific knockout mice. Graphical Abstract Network analysis of changes in gene co‐regulation, between large sets of Alzheimer's (AD) or Huntington's (HD) disease versus control brains, reveals that opposing dysregulation of two interacting processes, chromatin organization and neural differentiation, underlies both AD and HD.

Papillary thyroid carcinoma (PTC) is one of the most common endocrine carcinomas worldwide and the aetiology of this cancer is still not well understood. Therefore, it remains important to understand the disease mechanism and find prognostic biomarkers and/or drug candidates for PTC. Compared with approaches based on single‐gene assessment, network medicine analysis offers great promise to address this need. Accordingly, in the present study, we performed differential co‐expressed network analysis using five transcriptome datasets in patients with PTC and healthy controls. Following meta‐analysis of the transcriptome datasets, we uncovered common differentially expressed genes (DEGs) for PTC and, using these genes as proxies, found a highly clustered differentially expressed co‐expressed module: a ‘PTC‐module’. Using independent data, we demonstrated the high prognostic capacity of the PTC‐module and designated this module as a prognostic systems biomarker. In addition, using the nodes of the PTC‐module, we performed drug repurposing and text mining analyzes to identify novel drug candidates for the disease. We performed molecular docking simulations, and identified: 4‐demethoxydaunorubicin hydrochloride, AS605240, BRD‐A60245366, ER 27319 maleate, sinensetin, and TWS119 as novel drug candidates whose efficacy was also confirmed by in silico analyzes. Consequently, we have highlighted here the need for differential co‐expression analysis to gain a systems‐level understanding of a complex disease, and we provide candidate prognostic systems biomarker and novel drugs for PTC.

Differential expression analysis has led to the identification of important biomarkers in oesophageal squamous cell carcinoma (ESCC). Despite enormous contributions, it has not harnessed the full potential of gene expression data, such as interactions among genes. Differential co‐expression analysis has emerged as an effective tool that complements differential expression analysis to provide better insight of dysregulated mechanisms and indicate key driver genes. Here, we analysed the differential co‐expression of lncRNAs and protein‐coding genes (PCGs) between normal oesophageal tissue and ESCC tissues, and constructed a lncRNA‐PCG differential co‐expression network (DCN). DCN was characterized as a scale‐free, small‐world network with modular organization. Focusing on lncRNAs, a total of 107 differential lncRNA‐PCG subnetworks were identified from the DCN by integrating both differential expression and differential co‐expression. These differential subnetworks provide a valuable source for revealing lncRNA functions and the associated dysfunctional regulatory networks in ESCC. Their consistent discrimination suggests that they may have important roles in ESCC and could serve as robust subnetwork biomarkers. In addition, two tumour suppressor genes (AL121899.1 and ELMO2), identified in the core modules, were validated by functional experiments. The proposed method can be easily used to investigate differential subnetworks of other molecules in other cancers.

Background Network-based analysis of gene expression through co-expression networks can be used to investigate modular relationships occurring between genes performing different biological functions. An extended description of each of the network modules is therefore a critical step to understand the underlying processes contributing to a disease or a phenotype. Biological integration, topology study and conditions comparison (e.g. wild vs mutant) are the main methods to do so, but to date no tool combines them all into a single pipeline. Results Here we present GWENA, a new R package that integrates gene co-expression network construction and whole characterization of the detected modules through gene set enrichment, phenotypic association, hub genes detection, topological metric computation, and differential co-expression. To demonstrate its performance, we applied GWENA on two skeletal muscle datasets from young and old patients of GTEx study. Remarkably, we prioritized a gene whose involvement was unknown in the muscle development and growth. Moreover, new insights on the variations in patterns of co-expression were identified. The known phenomena of connectivity loss associated with aging was found coupled to a global reorganization of the relationships leading to expression of known aging related functions. Conclusion GWENA is an R package available through Bioconductor ( https://bioconductor.org/packages/release/bioc/html/GWENA.html ) that has been developed to perform extended analysis of gene co-expression networks. Thanks to biological and topological information as well as differential co-expression, the package helps to dissect the role of genes relationships in diseases conditions or targeted phenotypes. GWENA goes beyond existing packages that perform co-expression analysis by including new tools to fully characterize modules, such as differential co-expression, additional enrichment databases, and network visualization.

Background Gene co-expression networks represent modules of genes with shared biological function, and have been widely used to model biological pathways in gene expression data. Co-expression networks associated with a specific trait can be constructed and identified using weighted gene co-expression network analysis (WGCNA), which is especially useful for the study of transcriptional signatures in disease. WGCNA networks are typically constructed using both disease and wildtype samples, so molecular pathways associated with disease are identified. However, it would be advantageous to study such co-expression networks in their disease context across spatiotemporal conditions, but currently there is no comprehensive software implementation for this type of analysis. Results Here, we introduce a WGCNA-based procedure, multiWGCNA, that is tailored to datasets with variable spatial or temporal traits. As well as constructing the combined network, multiWGCNA also generates a network for each condition separately, and subsequently maps these modules between and across designs, and performs relevant downstream analyses, including module-trait correlation and module preservation. When applied to astrocyte-specific RNA-sequencing (RNA-seq) data from various brain regions of mice with experimental autoimmune encephalitis, multiWGCNA resolved the de novo formation of the neurotoxic astrocyte transcriptional program exclusively in the disease setting. Using time-course RNA-seq from mice with tau pathology (rTg4510), we demonstrate how multiWGCNA can also be used to study the temporal evolution of pathological modules over the course of disease progression. Conclusion The multiWGCNA R package can be applied to expression data with two dimensions, which is especially useful for the study of disease-associated modules across time or space. The source code and functions are freely available at: https://github.com/fogellab/multiWGCNA .

Background Elucidation of regulatory networks, including identification of regulatory mechanisms specific to a given biological context, is a key aim in systems biology. This has motivated the move from co-expression to differential co-expression analysis and numerous methods have been developed subsequently to address this task; however, evaluation of methods and interpretation of the resulting networks has been hindered by the lack of known context-specific regulatory interactions. Results In this study, we develop a simulator based on dynamical systems modelling capable of simulating differential co-expression patterns. With the simulator and an evaluation framework, we benchmark and characterise the performance of inference methods. Defining three different levels of “true” networks for each simulation, we show that accurate inference of causation is difficult for all methods, compared to inference of associations. We show that a z -score-based method has the best general performance. Further, analysis of simulation parameters reveals five network and simulation properties that explained the performance of methods. The evaluation framework and inference methods used in this study are available in the dcanr R/Bioconductor package. Conclusions Our analysis of networks inferred from simulated data show that hub nodes are more likely to be differentially regulated targets than transcription factors. Based on this observation, we propose an interpretation of the inferred differential network that can reconstruct a putative causal network.

Background Recent depression research has revealed a growing awareness of how to best classify depression into depressive subtypes. Appropriately subtyping depression can lead to identification of subtypes that are more responsive to current pharmacological treatment and aid in separating out depressed patients in which current antidepressants are not particularly effective. Differential co-expression analysis (DCEA) and differential regulation analysis (DRA) were applied to compare the transcriptomic profiles of peripheral blood lymphocytes from patients with two depressive subtypes: major depressive disorder (MDD) and subsyndromal symptomatic depression (SSD). Results Six differentially regulated genes (DRGs) (FOSL1, SRF, JUN, TFAP4, SOX9, and HLF) and 16 transcription factor-to-target differentially co-expressed gene links or pairs (TF2target DCLs) appear to be the key differential factors in MDD; in contrast, one DRG (PATZ1) and eight TF2target DCLs appear to be the key differential factors in SSD. There was no overlap between the MDD target genes and SSD target genes. Venlafaxine (Efexor™, Effexor™) appears to have a significant effect on the gene expression profile of MDD patients but no significant effect on the gene expression profile of SSD patients. Conclusion DCEA and DRA revealed no apparent similarities between the differential regulatory processes underlying MDD and SSD. This bioinformatic analysis may provide novel insights that can support future antidepressant R&D efforts.

Understanding the molecular mechanisms underlying diseases is crucial for more precise, personalized medicine. Pathway-level differential co-expression analysis, a powerful approach for transcriptomics, identifies condition-specific changes in gene-gene interaction networks, offering targeted insights. However, a key challenge is the lack of robust methods and benchmarks specifically for evaluating algorithms’ ability to identify disrupted gene-gene associations across conditions. We introduce DRaCOoN (Differential Regulatory and Co-expression Networks), a Python package and web tool for pathway-level differential co-expression analysis. DRaCOoN uniquely integrates multiple association and differential metrics, with a novel, computationally efficient permutation test for significance assessment. Crucially, DRaCOoN also provides a benchmarking framework for comprehensive method evaluation. Extensive benchmarking on simulated data and three real-world datasets (bone healing, colorectal cancer, and head/neck carcinoma) showed that DRaCOoN , particularly with an entropy-based association measure and the s differential metric, consistently outperforms eight other methods. It remains highly accurate in balanced datasets, robust to varying gene perturbation levels, and identifies biologically relevant regulatory changes. Furthermore, DRaCOoN serves as both a powerful tool and a benchmarking framework for elucidating disease mechanisms from transcriptomics data, advancing precision medicine by uncovering critical gene regulatory alterations.

Biological systems respond to perturbations through the rewiring of molecular interactions, organised in gene regulatory networks (GRNs). Among these, the increasingly high availability of transcriptomic data makes gene co-expression networks the most exploited ones. Differential co-expression networks are useful tools to identify changes in response to an external perturbation, such as mutations predisposing to cancer development, and leading to changes in the activity of gene expression regulators or signalling. They can help explain the robustness of cancer cells to perturbations and identify promising candidates for targeted therapy, moreover providing higher specificity with respect to standard co-expression methods. Here, we comprehensively review the literature about the methods developed to assess differential co-expression and their applications to cancer biology. Via the comparison of normal and diseased conditions and of different tumour stages, studies based on these methods led to the definition of pathways involved in gene network reorganisation upon oncogenes’ mutations and tumour progression, often converging on immune system signalling. A relevant implementation still lagging behind is the integration of different data types, which would greatly improve network interpretability. Most importantly, performance and predictivity evaluation of the large variety of mathematical models proposed would urgently require experimental validations and systematic comparisons. We believe that future work on differential gene co-expression networks, complemented with additional omics data and experimentally tested, will considerably improve our insights into the biology of tumours.

Background Brain implants have significant potential for therapeutic applications and neuroscience research, but complex tissue responses often compromise their long-term stability. To address this challenge, differential coexpression analysis can be used to identify key molecular regulators involved in brain implant responses. Results We developed DiffCoRank, an integrated framework that improves differential coexpression analysis by integrating the techniques of RNA-Seq data preprocessing, gene filtering, correlation-based module identification, and network analysis to discover differentially coexpressed gene clusters. A key innovation of our approach is false discovery rate (FDR) based selection of strongly connected genes (SCGs), by which we improve detection of strong coexpression patterns that otherwise could be lost to spurious correlations. To enhance the identification of different modules, we employ a hybrid clustering technique that combines uniform manifold approximation and projection (UMAP) with density-based spatial clustering of applications with noise (DBSCAN). We propose a multi-criteria hub gene ranking system incorporating network centrality metrics such as degree, closeness, betweenness, and eigenvector centrality to prioritise biologically relevant genes. Additionally, we created a user-friendly application to visualize and explore the results of DiffCoRank interactively. Conclusions Our method successfully identified key gene modules involved in oxidative stress, calcium signaling, immunological regulation, autophagic recovery, and vascular remodeling in RNA-Seq data of implanted rat brain tissue. Furthermore, we compared our results to those of other existing coexpression analysis frameworks, showing that our method successfully identifies unique regulatory processes and consistent coexpression patterns. Our research offers novel insights into the molecular processes that explain implant-tissue interactions and possible approaches to improve the robustness and biocompatibility of brain interfaces.